Wildcat DX Enhances Its Healthcare Portfolio
Wildcat DX, LLC has successfully acquired a full ownership stake in Navis Clinical Laboratories, Inc., a prominent provider of diagnostic lab testing services. The company remains committed to strengthening its position in the healthcare market by fostering innovation and excellence.
Stepping Into Leadership
As part of this strategic acquisition, Dr. Damon Borg will take on the role of interim CEO. Borg's leadership is expected to guide Navis Clinical Laboratories through this transitional phase, ensuring that the company continues to uphold its mission of delivering high-quality services to its clients.
Core Values and Commitment
The new ownership group deeply aligns with Navis' core values, including dedication to excellence and innovative approaches to diagnostic testing. This partnership aims to bolster Navis’ capabilities, allowing for enhanced production and service delivery across various healthcare needs.
Wildcat DX’s Expanding Portfolio
Navis Clinical Laboratories adds significant value to the already impressive array of healthcare companies owned by Wildcat DX, LLC. Their exceptional portfolio includes several key players in the healthcare sector.
Notable Companies Under Wildcat DX
Among the notable healthcare companies within Wildcat DX's portfolio are:
- Encore Wound Care, recognized as one of the largest mobile wound care practices nationwide, servicing various long-term care facilities with a strategic expansion planned into Indiana for 2025.
- Encore Surgical Supplies, a fast-growing company specializing in postoperative surgical dressing supplies, serving multiple medical practices across the country.
- MedArbor Diagnostics, located in Bristol, PA, offers a comprehensive range of molecular testing services.
- Novo Health Care Services, which focuses on technology and billing solutions for healthcare providers, enhancing operational efficiency in the industry.
Building on a Solid Foundation
The combined revenues of these healthcare entities are projected to exceed $200 million annually, demonstrating impressive year-over-year growth. This acquisition will align Navis Clinical Laboratories' strengths with the vast resources and networks developed by Wildcat DX.
Expanding Opportunities for Growth
Miro Kesic, Managing Partner of Wildcat DX, LLC, expressed excitement over this strategic acquisition. He emphasized the importance of Navis' strong reputation within the toxicology laboratory sector and highlighted the effort to maintain and enhance that reputation through effective integration into their expanding network.
Commitment to Excellence
Navis Clinical Laboratories remains steadfast in delivering high standards of corporate governance and transparency. The entire team is energized by the new opportunities this acquisition presents, promising growth and strategic advancements in their operations.
Contact Details for Further Information
If you would like to learn more about this exciting development, please reach out to:
Craig Waters, CFO (440) 652-8748
Frequently Asked Questions
What is the significance of Wildcat DX acquiring Navis Clinical Laboratories?
Wildcat DX's acquisition of Navis enhances its healthcare portfolio, allowing for improved services and integration of innovative diagnostic solutions.
Who will lead Navis Clinical Laboratories post-acquisition?
Dr. Damon Borg has been appointed as the interim CEO to guide Navis through the transition and ensure continued excellence in operations.
What are some companies owned by Wildcat DX?
Wildcat DX's portfolio includes Encore Wound Care, Encore Surgical Supplies, MedArbor Diagnostics, and Novo Health Care Services.
What is the expected financial outcome of the acquisition?
The combined healthcare entities under Wildcat DX are projected to exceed $200 million in yearly revenue with significant growth potential.
How does Navis maintain its commitment to quality?
Navis Clinical Laboratories emphasizes high standards of corporate governance and transparency throughout its operations, ensuring exceptional service delivery.
